<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39552877</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Effect of COVID-19 vaccine in adults infected with the Delta variant of SARS-CoV-2: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>6983</StartPage><EndPage>6998</EndPage><MedlinePgn>6983-6998</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd-24-1351</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Reducing mortality among those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a critical challenge in clinic. The objective of this study was to analyze the effect of the coronavirus disease 2019 (COVID-19) vaccine on the prognosis of individuals infected with the Delta variant of SARS-CoV-2.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In a single-center, retrospective cohort study, all adult patients with COVID-19 from designated hospital in Xi'an, China, during the Delta outbreak from December 2021 to January 2022 were enrolled. The patients were divided into two groups according to whether they received the COVID-19 vaccine, and differences in clinical outcomes (pneumonia, oxygen therapy, severe disease, and mechanical ventilation or death), symptoms, and nucleic acid-negative time between the two groups were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 651 adult patients with COVID-19 were included, among whom 578 were vaccinated and 73 were not vaccinated. Compared with the unvaccinated group, the vaccinated group had lower rates of pneumonia (49.8% <i>vs.</i> 67.1%; P=0.005), oxygen therapy (20.9% <i>vs.</i> 57.5%; P&lt;0.001), severe illness (1.6% <i>vs.</i> 26.0%; P&lt;0.001), and mechanical ventilation or mortality (0.3% <i>vs.</i> 13.7%; P&lt;0.001). Multivariate logistic regression analysis showed that COVID-19 vaccination significantly reduced the risk of requiring oxygen therapy, severe illness, and mechanical ventilation or death. Compared with the unvaccinated group, the vaccinated group had a higher incidence of sore throat (31.8% <i>vs.</i> 17.8%; P=0.01) and a lower incidence of shortness of breath (3.1% <i>vs.</i> 20.5%; P&lt;0.001), diarrhea (1.2% <i>vs.</i> 5.5%; P=0.03), and nausea or vomiting (1.4% <i>vs.</i> 6.8%; P=0.007). The median time of nucleic acid transition to negative was 14.0 [interquartile range (IQR), 10.0-17.0] and 15.0 (IQR, 11.0-18.0) days (P=0.18) in the vaccinated and unvaccinated groups, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Vaccination may reduce the risk of oxygen therapy, severe illness, and mechanical ventilation or death in patients with Delta variant COVID-19, as well as the incidence of pneumonia. Vaccinated patients had a higher incidence of sore throat and a lower incidence of shortness of breath, diarrhea, and nausea or vomiting compared to nonvaccinated patients. Vaccination did not shorten the time for the emergence of nucleic acid-negative status.</AbstractText><CopyrightInformation>2024 AME Publishing Company. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lv</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Xiaona</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tangdu Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yunfu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mingming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Liqiang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9808-6679</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019 vaccine (COVID-19 vaccine)</Keyword><Keyword MajorTopicYN="N">mechanical ventilation</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">oxygen therapy</Keyword><Keyword MajorTopicYN="N">pneumonia</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1351/coif). X.L. reports funding from Scientific Research Project of Air Force Equipment Comprehensive Research (No. KJ2023C0KYD23). L.S. reports funding from Key Projects of Basic Research of Natural Science in Shaanxi Province (No. 2022JZ-58). The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39552877</ArticleId><ArticleId IdType="pmc">PMC11565342</ArticleId><ArticleId IdType="doi">10.21037/jtd-24-1351</ArticleId><ArticleId IdType="pii">jtd-16-10-6983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021;27:1614-21. 10.1038/s41591-021-01446-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01446-y</ArticleId><ArticleId IdType="pubmed">34244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2022;22:439. 10.1186/s12879-022-07418-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07418-y</ArticleId><ArticleId IdType="pmc">PMC9077344</ArticleId><ArticleId IdType="pubmed">35525973</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819-29. 10.1016/S0140-6736(21)00947-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, McLaughlin JM, Khan F, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis 2022;22:357-66. 10.1016/S1473-3099(21)00566-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00566-1</ArticleId><ArticleId IdType="pmc">PMC8457761</ArticleId><ArticleId IdType="pubmed">34562375</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Hunt B, Stegemann M, et al. A living WHO guideline on drugs for covid-19. BMJ 2020;370:m3379. 10.1136/bmj.m3379</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Tao B, Li Z, et al. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. Int J Infect Dis 2022;116:204-9. 10.1016/j.ijid.2022.01.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.01.030</ArticleId><ArticleId IdType="pmc">PMC8769614</ArticleId><ArticleId IdType="pubmed">35065255</ArticleId></ArticleIdList></Reference><Reference><Citation>Arashiro T, Miwa M, Nakagawa H, et al. COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study). Vaccine 2024;42:677-88. 10.1016/j.vaccine.2023.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.12.033</ArticleId><ArticleId IdType="pubmed">38114409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YY, Choe YJ, Kim J, et al. Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study. J Korean Med Sci 2023;38:e87. 10.3346/jkms.2023.38.e87</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e87</ArticleId><ArticleId IdType="pmc">PMC10027545</ArticleId><ArticleId IdType="pubmed">36942395</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Xu S, Liu J, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022;20:400. 10.1186/s12916-022-02606-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02606-8</ArticleId><ArticleId IdType="pmc">PMC9583051</ArticleId><ArticleId IdType="pubmed">36266697</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam J, Rauf Ul Hassan M, Fatima Q, et al. Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-COV-2 in mixed variety of vaccine background. Saudi J Biol Sci 2022;29:103329. 10.1016/j.sjbs.2022.103329</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2022.103329</ArticleId><ArticleId IdType="pmc">PMC9155185</ArticleId><ArticleId IdType="pubmed">35668728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rearte A, Castelli JM, Rearte R, et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet 2022;399:1254-64. 10.1016/S0140-6736(22)00011-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00011-3</ArticleId><ArticleId IdType="pmc">PMC8923678</ArticleId><ArticleId IdType="pubmed">35303473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Sun W, Tang T, et al. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. Vaccine 2022;40:2869-74. 10.1016/j.vaccine.2022.03.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.067</ArticleId><ArticleId IdType="pmc">PMC8971107</ArticleId><ArticleId IdType="pubmed">35400561</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicini S, Bellini D, Iannarelli A, et al. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines. AJR Am J Roentgenol 2022;219:752-61. 10.2214/AJR.22.27843</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.22.27843</ArticleId><ArticleId IdType="pubmed">35642761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Zhang Y, Tang L, et al. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021. China CDC Wkly 2022;4:57-65. 10.46234/ccdcw2022.009</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2022.009</ArticleId><ArticleId IdType="pmc">PMC8837442</ArticleId><ArticleId IdType="pubmed">35186369</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Song R, Yuan Z, et al. Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022. Vaccines (Basel) 2022;10:1215. 10.3390/vaccines10081215</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081215</ArticleId><ArticleId IdType="pmc">PMC9413898</ArticleId><ArticleId IdType="pubmed">36016103</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Zamora E, Trujillo X, Huerta M, et al. First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence. Public Health 2022;207:105-7. 10.1016/j.puhe.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9020510</ArticleId><ArticleId IdType="pubmed">35594806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzuto A, Tammaro A, Tonini G, et al. COPD influences survival in patients affected by COVID-19, comparison between subjects admitted to an internal medicine unit, and subjects admitted to an intensive care unit: An Italian experience. J Med Virol 2021;93:1239-41. 10.1002/jmv.26585</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26585</ArticleId><ArticleId IdType="pmc">PMC7675494</ArticleId><ArticleId IdType="pubmed">33026657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzuto A, Tammaro A, Tonini G, et al. SARS-Cov-2 pneumonia and concurrent myelodysplasia complicated by Pseudomonas aeruginosa over-infection. J Virol Methods 2022;300:114419. 10.1016/j.jviromet.2021.114419</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114419</ArticleId><ArticleId IdType="pmc">PMC8660133</ArticleId><ArticleId IdType="pubmed">34896451</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan LM, McCormick DW, Lee C, et al. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison - Texas, July-August 2021. MMWR Morb Mortal Wkly Rep 2021;70:1349-54. 10.15585/mmwr.mm7038e3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7038e3</ArticleId><ArticleId IdType="pmc">PMC8459894</ArticleId><ArticleId IdType="pubmed">34555009</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Zhou Q, Huang X, et al. Effect of inactivated COVID-19 vaccine on the negative conversion of nucleic acid in asymptomatic or mild patients with COVID-19. BMC Infect Dis 2023;23:443. 10.1186/s12879-023-08315-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08315-8</ArticleId><ArticleId IdType="pmc">PMC10311841</ArticleId><ArticleId IdType="pubmed">37391716</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wen R, Li G, et al. Omicron variant of SARS-COV-2 in Shanghai: Clinical features and inactivated vaccine efficacy in 13,120 elderly patients. Int J Med Sci 2023;20:1144-51. 10.7150/ijms.84452</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.84452</ArticleId><ArticleId IdType="pmc">PMC10416717</ArticleId><ArticleId IdType="pubmed">37575277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J, Jeong H, Kim BH, et al. Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea. PLoS One 2023;18:e0290154. 10.1371/journal.pone.0290154</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0290154</ArticleId><ArticleId IdType="pmc">PMC10431655</ArticleId><ArticleId IdType="pubmed">37585419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Li Y, Pan Y, et al. Clinical and immune response characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a retrospective study. J Zhejiang Univ Sci B 2022;23:899-914. 10.1631/jzus.B2200054</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B2200054</ArticleId><ArticleId IdType="pmc">PMC9676093</ArticleId><ArticleId IdType="pubmed">36379610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020;395:1845-54. 10.1016/S0140-6736(20)31208-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31208-3</ArticleId><ArticleId IdType="pmc">PMC7255193</ArticleId><ArticleId IdType="pubmed">32450106</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;396:887-97. 10.1016/S0140-6736(20)31866-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zella D, Giovanetti M, Cella E, et al. The importance of genomic analysis in cracking the coronavirus pandemic. Expert Rev Mol Diagn 2021;21:547-62. 10.1080/14737159.2021.1917998</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2021.1917998</ArticleId><ArticleId IdType="pmc">PMC8095159</ArticleId><ArticleId IdType="pubmed">33849359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>